Iqvia Holdings Inc. (IQV) Financial Statements
Industry: Commercial Physical & Biological Research (Services)
In fiscal 2025, Iqvia reported revenue of $16.31B, up 5.9% from $15.40B the year before. Net income was $1.36B (a 8.3% net margin), or $7.84 per diluted share. Operating margin was 13.4%. Operating activities generated $2.65B of cash, leaving $2.05B of free cash flow. At fiscal year end, Iqvia held $29.94B in total assets against $23.31B in total liabilities, including $1.98B of cash and equivalents.
Open the full interactive Iqvia financials → Quarterly statements, key ratios, valuation history and price charts.
Iqvia Key Stats
| Share Price | $260.68 |
|---|---|
| Market Cap | $43.61B |
| P/E Ratio | 33.2 |
| Revenue YoY Growth | +5.9% |
| 52-Week Range | $156.66 – $275.02 |
| Shares Outstanding | 166.1 million (basic, 2026 Q2) |
Iqvia Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $11.36B | $13.87B | $14.41B | $14.98B | $15.40B | $16.31B |
| Operating Income | $731.0M | $1.39B | $1.80B | $1.98B | $2.20B | $2.18B |
| Pre-Tax Income | $373.0M | $1.13B | $1.36B | $1.46B | $1.67B | $1.59B |
| Income Tax | $72.0M | $163.0M | $260.0M | $101.0M | $301.0M | $252.0M |
| Net Income | $279.0M | $966.0M | $1.09B | $1.36B | $1.37B | $1.36B |
| Diluted EPS | $1.43 | $4.95 | $5.72 | $7.29 | $7.49 | $7.84 |
Iqvia Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $4.10B | $4.36B | $4.15B | $4.37B |
| Net Income | $331.0M | $514.0M | $274.0M | $256.0M |
| Diluted EPS | $1.93 | $2.96 | $1.61 | $1.53 |
Iqvia Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.81B | $1.37B | $1.22B | $1.38B | $1.70B | $1.98B |
| Current Assets | $5.09B | $4.76B | $4.98B | $5.60B | $5.83B | $6.25B |
| Total Assets | $24.56B | $24.69B | $25.34B | $26.68B | $26.90B | $29.94B |
| Current Liabilities | $4.56B | $5.24B | $5.58B | $6.49B | $6.96B | $8.34B |
| Total Long-Term Debt | $12.53B | $12.12B | $12.75B | $13.67B | $13.98B | $15.72B |
| Total Liabilities | $18.28B | $18.65B | $19.57B | $20.57B | $20.83B | $23.31B |
| Shareholders' Equity | $6.00B | $6.04B | $5.76B | $6.11B | $6.07B | $6.50B |
Iqvia Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $1.96B | $2.94B | $2.26B | $2.15B | $2.72B | $2.65B |
| Cash From Investing | -$796.0M | -$2.10B | -$2.01B | -$1.60B | -$1.44B | -$2.31B |
| Cash From Financing | -$217.0M | -$1.24B | -$329.0M | -$382.0M | -$878.0M | -$150.0M |
| Free Cash Flow | $1.34B | $2.30B | $1.59B | $1.50B | $2.11B | $2.05B |
Figures from Iqvia's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Iqvia financials page for every line item.
Iqvia Company Profile
| Ticker | IQV |
|---|---|
| Exchange | NYSE |
| Industry | Commercial Physical & Biological Research (Services) |
| Headquarters | Durham, North Carolina |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001478242 |
Frequently Asked Questions
What was Iqvia's revenue in fiscal 2025?
Iqvia (IQV) reported revenue of $16.31B for fiscal 2025.
What is Iqvia's annual revenue history?
Iqvia's annual revenue by fiscal year: 2020: $11.36B; 2021: $13.87B; 2022: $14.41B; 2023: $14.98B; 2024: $15.40B; 2025: $16.31B.
What was Iqvia's net income in fiscal 2025?
Iqvia reported net income of $1.36B for fiscal 2025.
What was Iqvia's earnings per share (EPS) in fiscal 2025?
Iqvia's diluted EPS was $7.84 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Iqvia generate in fiscal 2025?
Iqvia generated $2.05B of free cash flow in fiscal 2025.
What was Iqvia's revenue last quarter?
In its most recent reported quarter (2026 Q2), Iqvia reported revenue of $4.37B.
How much debt does Iqvia have?
Iqvia reported $15.72B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Iqvia are outstanding?
Iqvia reported a weighted average of 166.1 million basic shares outstanding in 2026 Q2.
What is Iqvia's market cap?
Based on its latest closing price, Iqvia (IQV) has a market capitalization of about $43.61B.
When does Iqvia's fiscal year end?
Iqvia's fiscal year end, as registered with the SEC, is December 31.
Where is Iqvia headquartered?
Iqvia lists its business address in Durham, North Carolina in its SEC filings.